Emerging Therapies in the Management of Advanced-Stage Gastric Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Gastric malignancy is a leading cause of cancer death globally, with limited treatment options for advanced stages.
• Current treatments, including trastuzumab and ramucirumab, offer modest benefits due to gastric cancer's molecular heterogeneity.
• The Cancer Genome Atlas (TCGA) classification identified distinct molecular subtypes, revealing new therapeutic targets.

Purpose of the Study:

• To review novel therapeutic agents for advanced-stage gastric cancer.
• To highlight compounds showing promise in early-phase studies.
• To focus on agents with planned or ongoing phase III trials.

Main Methods:

• Review of early-phase clinical trial data for novel gastric cancer compounds.
• Analysis of agents targeting molecular pathways, tumor microenvironments, and cancer stemness.
• Emphasis on agents progressing to phase III evaluation.

Main Results:

• Many agents targeting novel pathways have yielded disappointing results in randomized trials.
• Emerging strategies focus on modulating tumor microenvironments and cancer cell stemness.
• Several novel compounds demonstrate efficacy in early studies, warranting further investigation.

Conclusions:

• Despite challenges, novel therapeutic agents show promise for advanced gastric cancer.
• Focus on specific molecular subtypes and emerging strategies like targeting tumor microenvironment and stemness is crucial.
• Ongoing phase III trials are critical for validating new treatment options and improving patient outcomes.